Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 52.8% in January

Achilles Therapeutics plc (NASDAQ:ACHL - Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 57,800 shares, a decline of 52.8% from the January 15th total of 122,400 shares. Based on an average daily trading volume, of 620,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the company's stock are sold short.

Achilles Therapeutics Trading Down 0.7 %

Shares of ACHL stock traded down $0.01 during trading hours on Friday, reaching $1.38. 2,963,593 shares of the company's stock were exchanged, compared to its average volume of 973,781. The stock's 50 day moving average is $1.16 and its 200-day moving average is $1.00. The company has a market cap of $56.72 million, a price-to-earnings ratio of -0.84 and a beta of 1.32. Achilles Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.76.

Hedge Funds Weigh In On Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. BML Capital Management LLC raised its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHL - Free Report) by 555.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,100,002 shares of the company's stock after purchasing an additional 3,474,828 shares during the period. Achilles Therapeutics accounts for approximately 2.5% of BML Capital Management LLC's investment portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 at the end of the most recent quarter. 56.38% of the stock is currently owned by hedge funds and other institutional investors.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.